The CVS Health story

What drives the business

• CVS links insurance, pharmacy benefits and retail care through Aetna, CVS Caremark and CVS Pharmacy, with approximately 9,000 retail locations, more than 1,000 clinics and approximately 87 million pharmacy benefit plan members as of December 2025.
• The U.S. federal government is a significant customer: Health Care Benefits federal revenue represented approximately 20% of consolidated revenue in 2025, and contracts with the Centers for Medicare & Medicaid Services accounted for approximately 79% of consolidated federal revenue.
• Aetna exited its individual public exchange business effective January 2026, while improved Government business performance helped lower its medical benefit ratio to 87.4% in the quarter to June 2026 from 89.9% in the prior-year quarter.
• Health Services revenue grew 11.5% in the quarter to June 2026, driven by drug mix and brand inflation rather than higher claims volume, while improved purchasing economics and modest health care delivery improvement helped adjusted operating income rise 10.0%.
• Pharmacy & Consumer Wellness adjusted operating income rose 10.2% in the quarter to June 2026, supported by core pharmacy performance and Rite Aid asset acquisitions, although reimbursement pressure and drug price reductions constrained revenue growth.

What the price assumes

At $87.85, the reverse DCF implies free cash flow after stock pay grows at -3.2% a year for ten years, using a 10.2% discount rate.

That compares with delivered growth of 4.0% a year over the last 10 years and a TenQ check bar of 4.0%, so the implied rate is below both.

The 10.5% free cash flow yield is below CVS's historical comparison of 11.8%, while its 4.4% earnings yield falls short of the 5.2% Treasury yield used in the TenQ check.

Value CVS on your own assumptions

What could change the story

• Elevated medical costs remain a constraint because Aetna generally sets Commercial Insured premiums before the policy period and cannot recover unexpected cost increases within that period.
• Medicare quality ratings affect payments: more than 81% of Medicare Advantage members were in plans with 2026 ratings of at least 4.0 stars, compared with 88% for 2025 ratings, with the 2026 ratings determining bonus eligibility in 2027.
• A 2.0% operating margin leaves limited room for cost pressure and trails the 5.0% sector comparison used by TenQ.
• Total debt of $59.5 billion compares with $14.0 billion of cash and short-term investments, while interest coverage of 2.67 fails TenQ's 5.00 bar.
• The earnings recovery follows a weaker longer record, with profit growth over three years of -25.7% against TenQ's sector comparison of 2.8%.

What to watch next

• The full-year 2026 benchmarks are raised GAAP diluted EPS guidance of $6.84 to $7.04, adjusted EPS guidance of $7.90 to $8.10 and operating cash flow of at least $11.5 billion.
• Aetna's medical benefit ratio and adjusted operating income are the clearest measures of whether the Government recovery continues beyond the comparison with the prior-year premium deficiency reserve.
• Claims reserve development also matters after prior years' health care cost estimates developed favorably by $1.2 billion in the six months to June 2026, alongside days claims payable of 41.7 days at June 2026.
• Pharmacy results will show whether prescription growth and purchasing economics continue to offset reimbursement pressure and improved pricing for pharmacy benefit clients.

Sources

• CVS Health's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The CVS stock report, for every figure and check